Cargando…
iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
BACKGROUND: The aims of our study were to identify serum biomarkers that distinguish pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) patients from benign pancreatic disease patients and healthy subjects, and to assess the effects of jaundice on biomarker performance. METHODS: Isobaric tag...
Autores principales: | Tonack, S, Jenkinson, C, Cox, T, Elliott, V, Jenkins, R E, Kitteringham, N R, Greenhalf, W, Shaw, V, Michalski, C W, Friess, H, Neoptolemos, J P, Costello, E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658525/ https://www.ncbi.nlm.nih.gov/pubmed/23579209 http://dx.doi.org/10.1038/bjc.2013.150 |
Ejemplares similares
-
Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma
por: Nishimura, K, et al.
Publicado: (2014) -
S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility
por: Nedjadi, T, et al.
Publicado: (2009) -
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
por: Dive, C, et al.
Publicado: (2010) -
i-Tracker: For quantitative proteomics using iTRAQ™
por: Shadforth, Ian P, et al.
Publicado: (2005) -
iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer
por: Rehman, Ishtiaq, et al.
Publicado: (2012)